156 related articles for article (PubMed ID: 34820261)
1. Eosinophilia characterized by a rare CCT6B mutation and responsive to tyrosine kinase inhibition: Case report and literature review.
Singh A; Baron J; Singh N; Peringeth G; Wang ES
Leuk Res Rep; 2021; 16():100279. PubMed ID: 34820261
[TBL] [Abstract][Full Text] [Related]
2. Chronic eosinophilic leukemia: a case report and review of literature.
Kumar A; Sinha S; Tripathi AK
Indian J Hematol Blood Transfus; 2007 Dec; 23(3-4):112-5. PubMed ID: 23100928
[TBL] [Abstract][Full Text] [Related]
3. A novel activating JAK1 mutation in chronic eosinophilic leukemia.
Shomali W; Damnernsawad A; Theparee T; Sampson D; Morrow Q; Yang F; Fernandez-Pol S; Press R; Zehnder J; Tyner JW; Gotlib J
Blood Adv; 2021 Sep; 5(18):3581-3586. PubMed ID: 34496019
[TBL] [Abstract][Full Text] [Related]
4. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
[TBL] [Abstract][Full Text] [Related]
5. Intermediate between Idiopathic Hypereosinophilia and Chronic Eosinophilic Leukemia: A Report of Two Hypereosinophilic Cases with Possible Novel Molecular Mutations.
Choudhuri J; Eskandari M; Shi Y; Wang Y
Case Rep Hematol; 2021; 2021():1142124. PubMed ID: 34513100
[TBL] [Abstract][Full Text] [Related]
6. [The idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia].
Chrobák L; Voglová J
Vnitr Lek; 2005 Dec; 51(12):1385-93. PubMed ID: 16430106
[TBL] [Abstract][Full Text] [Related]
7. A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia.
Hofmans M; Delie A; Vandepoele K; Van Roy N; Van der Meulen J; Philippé J; Moors I
Leuk Res Rep; 2018; 9():45-47. PubMed ID: 29892549
[TBL] [Abstract][Full Text] [Related]
8. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S; Gotlib J
Semin Cancer Biol; 2004 Feb; 14(1):23-31. PubMed ID: 14757533
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.
Wang SA; Hasserjian RP; Tam W; Tsai AG; Geyer JT; George TI; Foucar K; Rogers HJ; Hsi ED; Rea BA; Bagg A; Bueso-Ramos CE; Arber DA; Verstovsek S; Orazi A
Haematologica; 2017 Aug; 102(8):1352-1360. PubMed ID: 28495918
[TBL] [Abstract][Full Text] [Related]
10. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
[TBL] [Abstract][Full Text] [Related]
12. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
[TBL] [Abstract][Full Text] [Related]
13. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
14. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S; Gotlib J
Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431
[TBL] [Abstract][Full Text] [Related]
15. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
16. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.
Qu SQ; Qin TJ; Xu ZF; Zhang Y; Ai XF; Li B; Zhang HL; Fang LW; Pan LJ; Hu NB; Xiao ZJ
Oncotarget; 2016 May; 7(22):33229-36. PubMed ID: 27120808
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.
Gotlib J
Curr Hematol Malig Rep; 2015 Dec; 10(4):351-61. PubMed ID: 26404639
[TBL] [Abstract][Full Text] [Related]
19. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
20. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]